Skip to main content Skip to main navigation menu Skip to site footer

Correlation of testosterone and ESR2 in prostate cancer

  • Hotman Christinus ,
  • Raden Danarto ,
  • Indrawarman Soerohardjo ,
  • Ery Kus Dwianingsih ,
  • Yurisal Akhmad Dany ,

Abstract

Introduction: Prostate cancer (PCa), as the second most frequent cancer in males, has a significant challenge in determining differential diagnosis and prognosis of aggressive or non-aggressive prostate cancer. For functioning correctly, the prostate needs sex steroid hormones, which are also factors in the initiation and progression of carcinogenesis. Risk and Gleason score upgrading can be predicted by preoperative plasma testosterone levels in men with prostate cancer undergoing radical prostatectomy. Not only testosterone but estrogen also has roles in prostate cancer carcinogenesis. Estrogen Receptor 2 (ESR2) gene has been found to encode ER-β, which has an anti-proliferative effect on prostate tissue. This study aims to look up any correlation between testosterone and ESR2 in prostate cancer.

Methods: This is an analytic cross-sectional study. We conducted a quantitative real-time polymerase chain reaction (qPCR) examination involving 15 benign prostate hyperplasia (BPH), 10 non-metastasized PCa, and 21 PCa patients for determining ESR2 expression from formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue with known testosterone level in our institution. Data were analyzed using statistical tests with a significance of p <0.05.

Results: The mean testosterone level and ESR2 expression are 785 ng/dl and 236.4 ng/dl 4.6 8.2, respectively, in BPH and PCa. Statistically, there was an inverse correlation between testosterone and ESR2 levels in prostate cancer (p<0.05).

Conclusion: This study found lower testosterone correlates with ESR2 modulation.

Section

References

  1. Zhai Z, Zheng Y, Li N, et al. Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017. Cancer. 2020;126(9):1969-1978. doi:10.1002/cncr.32733
  2. Mochtar CA, Atmoko W, Umbas R, Hamid ARAH. Prostate cancer detection rate in Indonesian men. Asian Journal of Surgery. 2018;41(2):163-169. doi:10.1016/j.asjsur.2017.01.001
  3. Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate-specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020;10(1):20015. doi:10.1038/s41598-020-76786-9
  4. Shah A, Shah AA, K N, Lobo R. Mechanistic targets for BPH and prostate cancer–a review. Reviews on Environmental Health. 2021;36(2):261-270. doi:10.1515/reveh-2020-0051
  5. Skinder D, Zacharia I, Studin J, Covino J. Benign prostatic hyperplasia: A clinical review. Journal of the American Academy of Physician Assistants. 2016;29(8):19-23. doi:10.1097/01.JAA.0000488689.58176.0a
  6. McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. CMAR. 2020;Volume 12:5225-5241. doi:10.2147/CMAR.S250829
  7. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Therapeutic Advances in Urology. 2015;7(6):378-387. doi:10.1177/1756287215597633
  8. Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(2):185-194. doi:10.1038/s41391-018-0081-6
  9. Raven G, De Jong FH, Kaufman JM, De Ronde W. In Men, Peripheral Estradiol Levels Directly Reflect the Action of Estrogens at the Hypothalamo-Pituitary Level to Inhibit Gonadotropin Secretion. The Journal of Clinical Endocrinology & Metabolism. 2006;91(9):3324-3328. doi:10.1210/jc.2006-0462
  10. Morais-Santos M, Nunes AEB, Oliveira AG, et al. Changes in Estrogen Receptor ERβ (ESR2) Expression without Changes in the Estradiol Levels in the Prostate of Aging Rats. Koul HK, ed. PLoS ONE. 2015;10(7):e0131901. doi:10.1371/journal.pone.0131901
  11. Lafront C, Germain L, Weidmann C, Audet-Walsh É. A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation. Sci Rep. 2020;10(1):4024. doi:10.1038/s41598-020-60844-3
  12. Tan RBW, Silberstein JL, Hellstrom WJG. Testosterone and the Prostate. Sexual Medicine Reviews. 2014;2(3-4):112-120. doi:10.1002/smrj.29
  13. Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118(5):731-741. doi:10.1111/bju.13417
  14. Watts EL, Appleby PN, Perez-Cornago A, et al. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. European Urology. 2018;74(5):585-594. doi:10.1016/j.eururo.2018.07.024
  15. Watts EL, Fensom GK, Smith Byrne K, et al. Circulating insulin‐like growth factor‐I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank. Intl Journal of Cancer. 2021;148(9):2274-2288. doi:10.1002/ijc.33416
  16. Towe MM, Huynh LM, El Khatib F, Osman MM, Yafi FA, Ahlering TE. The predictive power of free (vs. total) testosterone in aggressive prostate cancer. JCO. 2019;37(15_suppl):e16570-e16570. doi:10.1200/JCO.2019.37.15_suppl.e16570
  17. Miura N, Mori K, Mostafaei H, et al. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(11):1881-1891. doi:10.1007/s10147-020-01747-1
  18. Carruba G. Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario. J Cell Biochem. 2007;102(4):899-911. doi:10.1002/jcb.21529
  19. Bosland MC. A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Letters. 2013;334(1):28-33. doi:10.1016/j.canlet.2012.08.027
  20. Aversa C, Jime N, Font A, et al. Estrogen receptor β and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer.
  21. Chang X, Yang Z, Wang H, Wang Y, Li J, Han Z. ESR2 Polymorphisms on Prostate Cancer Risk: A Systematic Review and Meta-Analysis. In Review; 2022. doi:10.21203/rs.3.rs-1824385/v1
  22. Lidaka L, Bekere L, Rota A, et al. Role of Single Nucleotide Variants in FSHR, GNRHR, ESR2 and LHCGR Genes in Adolescents with Polycystic Ovary Syndrome. Diagnostics. 2021;11(12):2327. doi:10.3390/diagnostics11122327

How to Cite

Christinus, H., Danarto, R. ., Soerohardjo, I. ., Dwianingsih, E. K. ., & Dany, Y. A. . (2024). Correlation of testosterone and ESR2 in prostate cancer. Indonesia Journal of Biomedical Science, 18(1), 162–165. https://doi.org/10.15562/ijbs.v18i1.564

HTML
10

Total
22

Share

Search Panel

Hotman Christinus
Google Scholar
Pubmed
IJBS Journal


Raden Danarto
Google Scholar
Pubmed
IJBS Journal


Indrawarman Soerohardjo
Google Scholar
Pubmed
IJBS Journal


Ery Kus Dwianingsih
Google Scholar
Pubmed
IJBS Journal


Yurisal Akhmad Dany
Google Scholar
Pubmed
IJBS Journal